Skip to main content
. Author manuscript; available in PMC: 2016 Jan 21.
Published in final edited form as: Expert Opin Investig Drugs. 2013 Nov 20;23(2):243–254. doi: 10.1517/13543784.2014.852536

Figure 2. GLYX-13 is a cognitive enhancer.

Figure 2

(A– C) The effects of an optimal cognitive enhancing dose of GLYX-13 (1 mg/kg, IV, 15 min post-dosing) in young adult (3 months) or learning-impaired aged (27 months old) rats in hippocampal-dependent trace eyeblink conditioning (A), alternating T-maze (B), and Morris water maze (C) tests. (D) GLYX-13 (1 mg/kg, IV, 15 min post-dosing) in young adult (3 months) rats facilitated positive emotional learning as measured by rates of hedonic 50 kHz ultrasonic vocalizations in response to a conditioned stimulus that predicts heterospecific rough-and-tumble play.

Data are expressed as Mean ± SEM. *p < 0.05 Fisher’s PLSD post hoc test vs. vehicle.

Data adapted from [30,31,33] with permission of Elsevier.